High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria
暂无分享,去创建一个
J. Harwell | O. Agbaji | Jennifer Campbell | C. Amole | A. Akanmu | Owens Wiwa | James Conroy | Ikechukwu Amamilo | Damien Anweh | Opeyemi Abudiore | W. Eigege | Justus Jiboye | F. Lufadeju